165 related articles for article (PubMed ID: 15648545)
1. Plasma and tissue chromogranin in patients with adrenocortical adenomas.
Bernini GP; Moretti A; Borgioli M; Bardini M; Miccoli P; Berti P; Basolo F; Faviana P; Birindelli R; Salvetti A
J Endocrinol Invest; 2004 Oct; 27(9):821-5. PubMed ID: 15648545
[TBL] [Abstract][Full Text] [Related]
2. Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors.
Bernini G; Moretti A; Fontana V; Orlandini C; Miccoli P; Berti P; Basolo F; Faviana P; Bardini M; Salvetti A
Eur J Endocrinol; 2004 Aug; 151(2):215-22. PubMed ID: 15296477
[TBL] [Abstract][Full Text] [Related]
3. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma.
Cotesta D; Caliumi C; Alò P; Petramala L; Reale MG; Masciangelo R; Signore A; Cianci R; D'Erasmo E; Letizia C
Tumori; 2005; 91(1):53-8. PubMed ID: 15850005
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A as serum marker of pituitary adenomas.
Gussi IL; Young J; Baudin E; Bidart JM; Chanson P
Clin Endocrinol (Oxf); 2003 Nov; 59(5):644-8. PubMed ID: 14616890
[TBL] [Abstract][Full Text] [Related]
5. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
6. [Adrenocortical tumors with neuroendocrine differentiation].
Kazantseva IA; Poliakova GA; Gurevich LG; Morozov IA; Bezuglova TV; Smirnov VB
Arkh Patol; 2002; 64(5):8-13. PubMed ID: 12575533
[TBL] [Abstract][Full Text] [Related]
7. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin 'A' in normal subjects, essential hypertensives and adrenalectomized patients.
Giampaolo B; Angelica M; Antonio S
Clin Endocrinol (Oxf); 2002 Jul; 57(1):41-50. PubMed ID: 12100068
[TBL] [Abstract][Full Text] [Related]
9. Plasma and salivary 6beta-hydroxycortisol measurements for assessing adrenocortical activity in patients with adrenocortical adenomas.
Varga I; Jakab C; Szücs N; Patócs A; Tóth M; Kiss R; Gláz E; Rácz K
Horm Metab Res; 2003 Jul; 35(7):421-6. PubMed ID: 12931273
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.
Heaney AP; Curry WJ; Pogue KM; Armstrong VL; Mirakhur M; Sheridan B; Johnston CF; Buchanan KD; Atkinson AB
Pituitary; 2000 Oct; 3(2):67-75. PubMed ID: 11141698
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of MMP-1, MMP-8, MMP-9 serum levels in patients with adrenal tumors prior to and after surgery.
Kołomecki K; Stepień H; Bartos M; Narebski J
Neoplasma; 2001; 48(2):116-21. PubMed ID: 11478691
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands.
Takiyyuddin MA; Cervenka JH; Pandian MR; Stuenkel CA; Neumann HP; O'Connor DT
J Clin Endocrinol Metab; 1990 Aug; 71(2):360-9. PubMed ID: 2116438
[TBL] [Abstract][Full Text] [Related]
13. Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies.
Takiyyuddin MA; Baron AD; Cervenka JH; Barbosa JA; Neumann HP; Parmer RJ; Sullivan PA; O'Connor DT
J Clin Endocrinol Metab; 1991 Mar; 72(3):616-22. PubMed ID: 1671783
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
[TBL] [Abstract][Full Text] [Related]
15. [The expression and significance of chromogranin A and synaptophysin in adrenal gland tumors].
Feng C; Li HZ; Yan WG; Luo YF; Cao JL
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):486-8. PubMed ID: 16188147
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.
Lloyd RV; Jin L; Qian X; Scheithauer BW; Young WF; Davis DH
Am J Pathol; 1995 May; 146(5):1188-98. PubMed ID: 7747813
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro evidence for the production of inhibin-like immunoreactivity in human adrenocortical adenomas and normal adrenal glands: relatively high secretion from adenomas manifesting Cushing's syndrome.
Nishi Y; Haji M; Takayanagi R; Yanase T; Ikuyama S; Nawata H
Eur J Endocrinol; 1995 Mar; 132(3):292-9. PubMed ID: 7889177
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
Stridsberg M; Husebye ES
Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
[TBL] [Abstract][Full Text] [Related]
19. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms.
Erickson LA; Jin L; Sebo TJ; Lohse C; Pankratz VS; Kendrick ML; van Heerden JA; Thompson GB; Grant CS; Lloyd RV
Endocr Pathol; 2001; 12(4):429-35. PubMed ID: 11949624
[TBL] [Abstract][Full Text] [Related]
20. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]